On November 5, 2024, Tarsus Pharmaceuticals (Irvine, CA, USA) announced the appointment of Dr. Elizabeth Yeu as Chief Medical Officer (CMO) to its leadership team.
Formerly Tarsus’ Chief Medical Advisor and a board member, Dr. Yeu will now lead the company’s medical affairs and pharmacovigilance teams, including evidence generation, medical education, and oversight of patient safety.
Dr. Yeu’s appointment comes over a year after the July 2023 approval of XDEMVY® (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis.
Tarsus’ current pipeline includes a potential expansion for XDEMVY to the treatment of meibomian gland disease, a preservative-free formulation of XDEMVY, and investigational drugs TP-04 (Phase II) for the treatment of rosacea, and TP-05 (Phase II), an oral tablet for Lyme disease prevention.
With her extensive background in clinical practice and ophthalmic research, Dr. Yeu brings experience and insight that Tarsus believes will support its mission to address these complex medical challenges.
“Liz has been an invaluable partner and advisor to Tarsus, and we are thrilled to apply her medical expertise and leadership directly to enhancing the impact of our medical organization,” said Dr. Bobby Azamian, Tarsus CEO and Chairman, in a news release. “Her unique clinical perspective will be critical to our continued success and leadership in eye care and beyond.”
“I’m fortunate to have been a part of the Tarsus journey since the early days and am delighted for the opportunity to work even more closely with such a talented and passionate team,” said Dr. Yeu. “I look forward to contributing full time to the Company’s efforts to deliver novel therapies…to more patients and ensuring my fellow clinicians have the evidence and information they need to provide optimal care to their patients.”
Who is Dr. Yeu?
Dr. Elizabeth Yeu has a solid reputation in the field of ophthalmology, built over a career that spans clinical care, surgery, research, and education. Following her residency at the Wilmer Eye Institute at Johns Hopkins, she has worked as a partner and practicing ophthalmologist at Virginia Eye Consultants and an assistant professor at the Baylor College of Medicine’s Cullen Eye Institute and Eastern Virginia Medical School.
She also serves on a number of national ophthalmic medical boards and committees, including the American Board of Ophthalmology (ABO) and the Refractive Surgery Section of the Annual Meeting Program Committee for the American Academy of Ophthalmology (AAO). Additionally, Dr. Yeu was the former president of the American Society of Cataract and Refractive Surgery (ASCRS).
Known for her contributions in cataract and refractive surgery as well as dry eye management, Dr. Yeu has been a proponent of new, patient-focused approaches in ophthalmology.
